Ethinylestradiol + Ferrous Fumarate + Norgestrel is indicated for the prevention of pregnancy.

Prevention of Pregnancy

• Take one tablet by mouth at the same time every day for 28 days.
• Take tablets in the order directed on the blister pack.

The most common adverse reactions associated with Ethinylestradiol + Ferrous Fumarate + Norgestrel include nausea, vomiting, headache, acne, vaginal bleeding/ discharge, increased appetite & breast tenderness. Other less common side effects may include mood changes, fluid retention, changes in libido, and weight gain. Rare but serious adverse reactions may include blood clots, liver tumors, and hypertension.

Nausea

Headache

Breast Tenderness

Vaginal Discharge

Before prescribing Ethinylestradiol + Ferrous Fumarate + Norgestrel, the following warnings and precautions should be considered:

• Cardiovascular Risk: The use of COCs is associated with an increased risk of cardiovascular events such as myocardial infarction, stroke, and venous thromboembolism. Patients with a history of cardiovascular disease or risk factors should be closely monitored.
• Thromboembolism: COCs increase the risk of venous thromboembolism, particularly in patients with a history of thrombosis or thromboembolism, and in those who are immobilized. Patients should be advised to discontinue use of COCs and seek medical attention if they experience symptoms of thromboembolism.
• Cancer Risk: The use of COCs has been associated with an increased risk of breast cancer, cervical cancer, and liver cancer. Patients with a history of cancer should be closely monitored.
• Hepatic Impairment: COCs are metabolized by the liver, and patients with hepatic impairment may be at increased risk of adverse reactions. The use of COCs should be avoided in patients with severe liver disease.
• Interactions: COCs may interact with other medications, including antibiotics, anticonvulsants, and herbal supplements. Patients should be advised to inform their healthcare provider of all medications and supplements they are taking.
• Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking Ethinylestradiol + Ferrous Fumarate + Norgestrel. Consider an alternative contraceptive method for women with uncontrolled dyslipidemia. 
• Headache: Evaluate significant change in headaches and discontinue Ethinylestradiol + Ferrous Fumarate + Norgestrel if indicated.
• Bleeding Irregularities and Amenorrhea: Evaluate irregular bleeding or amenorrhea.